ImmuDyne Sales Continue to Improve, Sees Earnings Ahead

Oct 01, 2015 OTC Disclosure & News Service MT. KISCO, N.Y., Oct. 01, 2015, OTCQB, IMMD, (GLOBE NEWSWIRE) ImmuDyne, Inc. (OTCQB:IMMD) ImmuDyne today announced nine month revenues grew to $844,268 in 2015 from $554,509 in 2014. Revenues for the 3rd quarter rose 40%, year over year, to approximately $279,000. As previously reported, ImmuDyne is capitalizing on its strong Intellectual Property and is pursuing additional sales and marketing opportunities, while continuing strong expense controls. ImmuDyne President and CEO, Mark McLaughlin commented, “ImmuDyne is now approaching positive cash flow and earnings, and the Company continues to execute on new sales opportunities. With about 30 million shares outstanding and no material debt, any incremental sales growth will be meaningful to the bottom line.” ImmuDyne Chief Medical Officer Sven Rohmann M.D., PhD, M.B.A. stated, “In addition to the improved sales reported thus far in 2015, there are significant new market opportunities for


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: